Prostate cancer and colorectal cancer share a surprising number of risk factors, from the foods you eat to how much you move to the composition of bacteria in your gut. They are the two most commonly diagnosed non-skin cancers in men, and understanding where their biology overlaps can simplify prevention: many of the same lifestyle choices that lower your odds of one also lower your odds of the other. The overlap is not total, though, and some risk factors affect one cancer far more than the other.
The Epidemiological Link Between the Two Cancers
One of the clearest hints that prostate and colorectal cancer share underlying biology comes from studies tracking whether having one raises your risk of the other. A large Korean cohort study followed men who had been treated for colorectal cancer and found that their rate of developing a new prostate cancer was roughly double that of men without a colorectal cancer history. The risk was even more pronounced in younger men: those under 55 had nearly nine times the hazard of developing prostate cancer compared to same-age controls.1PubMed Central. Secondary Primary Prostate Cancer after Colorectal Cancer: A Nationwide Population-based Cohort Study in Korea
Family history tells a similar story, with a twist. In a large analysis from the Women’s Health Initiative, having a first-degree relative with prostate cancer alone did not raise a woman’s colorectal cancer risk in a meaningful way. But having relatives with both prostate and colorectal cancer was associated with roughly a 50% increase in colorectal cancer risk, similar to the bump seen with a family history of colorectal cancer alone.2PubMed Central. Family history of prostate and colorectal cancer and risk of colorectal cancer in the Women’s health initiative The pattern suggests that in families where both cancers cluster, shared genetic or environmental factors are at work.
Red Meat, Processed Meat, and Ultra-Processed Foods
Diet is the risk factor where the two cancers overlap most visibly in public health messaging, and with good reason. Processed meat has been classified as carcinogenic to humans for colorectal cancer, and the mechanisms that drive that classification apply to other tissues as well. Heme iron from red meat catalyzes oxidative reactions that can damage DNA and cell membranes. When meat is cooked at high temperatures, it generates compounds called heterocyclic amines and polycyclic aromatic hydrocarbons, both of which are mutagenic. Processed meats carry the additional burden of N-nitroso compounds formed from nitrites reacting with proteins.3PubMed Central. Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence
These same compounds reach the prostate through the bloodstream. One specific heterocyclic amine found in cooked meat, known as PhIP, has been shown to form DNA-damaging complexes in human prostate tissue specifically, which can trigger abnormal cell growth. The fat in red meat may also stimulate hormone production, including estrogens, potentially fueling hormone-sensitive cancers like those of the prostate.4PubMed Central. Association Between Red and Processed Meat Consumption and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis
Ultra-processed foods are a newer area of concern. A study drawing from three large US cohorts found that men in the highest category of ultra-processed food consumption had about a 29% higher risk of colorectal cancer than those who ate the least. The association was especially strong for cancers of the distal colon, where risk jumped by roughly 72%. Interestingly, no such link was found in women in the same study.5PubMed Central. Association of ultra-processed food consumption with colorectal cancer risk among men and women: results from three prospective US cohort studies A separate population-based study confirmed a link between ultra-processed food intake and colorectal cancer but found no association with prostate cancer risk.6PubMed. Consumption of ultra-processed foods and drinks and colorectal, breast, and prostate cancer So while the broad dietary pattern of heavy meat and processed food intake is a shared concern, ultra-processed foods seem to hit the colon harder than the prostate.
Obesity, Insulin, and Growth Signals
Carrying excess body fat, especially around the midsection, is a well-established risk factor for colon cancer. High BMI, physical inactivity, and visceral adiposity are consistent risk factors for both colon cancer and precancerous polyps.7Gastroenterology. The Role of Obesity and Related Metabolic Disturbances in Cancers of the Colon, Prostate, and Pancreas The relationship with prostate cancer is more complicated: obesity is more strongly tied to aggressive or advanced-stage prostate cancer than to the disease overall.
The biological pathway linking obesity to both cancers runs through insulin and insulin-like growth factor 1 (IGF-1). When your body becomes resistant to insulin, it compensates by producing more of it. That excess insulin suppresses the proteins that normally keep IGF-1 in check, letting more of it circulate freely. IGF-1 is a potent growth signal that tells cells to multiply and resist the programmed death that normally clears away damaged cells.8PubMed Central. The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy In the prostate, excess insulin also drives down sex hormone-binding globulin, which effectively increases the amount of free testosterone available to fuel prostate cell growth.9PubMed. Prostate cancer: another aspect of the insulin-resistance syndrome? So the same metabolic dysfunction feeds two different cancers through slightly different downstream paths.
The Gut Microbiome Connects Both Sites
The link between gut bacteria and colorectal cancer has been studied for years, but researchers are now finding that your gut microbiome also influences what happens in the prostate. The concept of a “gut-prostate axis” has emerged, with evidence that bacterial metabolites produced in the gut can leak into the bloodstream and reach distant organs, including the prostate.10PubMed Central. The Gut-Prostate Axis: A New Perspective of Prostate Cancer Biology through the Gut Microbiome
One telling experiment used mice whose gut bacteria were disrupted by antibiotics. The disturbed microbiome led to an overgrowth of harmful bacteria, increased gut permeability, and higher levels of a bacterial toxin called lipopolysaccharide (LPS) inside prostate tumors. That intratumoral LPS activated an inflammatory signaling cascade that sped up tumor growth and even made the cancer more resistant to chemotherapy.11PubMed Central. Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis This is still early-stage research, but it reinforces the idea that gut health is not just a colon cancer issue.12PubMed Central. Emerging Relationship between the Gut Microbiome and Prostate Cancer
The flip side is that a healthy microbiome produces beneficial compounds. When gut bacteria ferment dietary fiber, they generate butyrate, a short-chain fatty acid with confirmed anti-cancer properties. Butyrate activates receptors and inhibits enzymes involved in cancer cell growth.13PubMed Central. Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic This is one reason high-fiber diets show up consistently in colorectal cancer prevention recommendations, and it may partly explain the gut-prostate connection as well.
Chronic Inflammation as a Shared Driver
Inflammation is one of the broadest shared mechanisms behind both cancers. When tissue stays inflamed over long periods, the persistent signaling environment encourages cell turnover, DNA errors, and immune suppression. Specific inflammatory molecules, including IL-17 and TNF-alpha, have been shown to increase PD-L1 expression in both human prostate and colon cancer cell lines.14PubMed Central. Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells PD-L1 is the protein that cancer cells use to hide from the immune system, so when inflammation drives its production up, tumors in either location can evade detection more effectively.
Estrogen receptor beta (ERβ) offers another shared angle. This receptor normally acts as a tumor suppressor in both the prostate and the colon. When ERβ signaling is intact, it slows cell proliferation and opposes the growth-promoting effects of other estrogen receptors.15Bioscientifica Journals. Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS Loss of ERβ expression is observed in both prostate and colorectal tumors, which is part of why hormonal disruption matters for both diseases.
Physical Activity Protects Against Both
Exercise is one of the strongest modifiable protections you have, and the evidence holds for both cancers. A systematic review for the US Physical Activity Guidelines Advisory Committee found that comparing the most active people to the least active, colon cancer risk dropped by roughly 19%. The benefit extended well past diagnosis: colorectal cancer survivors in the highest activity category had about a 42% lower risk of dying from any cause and a 38% lower risk of dying from their cancer specifically.16PubMed Central. Physical Activity in Cancer Prevention and Survival: A Systematic Review
The numbers for prostate cancer are strikingly similar in the survivorship phase. Prostate cancer survivors with the highest levels of physical activity had a 38% reduction in cancer-specific mortality compared to the least active group.16PubMed Central. Physical Activity in Cancer Prevention and Survival: A Systematic Review The mechanisms likely include the metabolic benefits already discussed: exercise improves insulin sensitivity, reduces circulating IGF-1, lowers systemic inflammation, and helps maintain a healthier body weight. The practical takeaway is straightforward: regular movement helps at every stage, from prevention through treatment and survivorship.
Protective Nutrients Worth Knowing About
Fiber deserves its own mention beyond its role in butyrate production. A fiber-rich diet feeds the beneficial bacteria that keep your gut lining intact, reducing the kind of bacterial leakage linked to both colorectal and prostate inflammation. But two other dietary compounds show up repeatedly in research on both cancers.
Vitamin D has a well-documented inverse relationship with both cancers. Low blood levels of 25-hydroxyvitamin D (the form your doctor measures) have been correlated with higher incidence of colorectal, prostate, and breast cancers. The active form of vitamin D acts on receptors throughout the body, slowing cell division and promoting normal cell maturation. Researchers have proposed that adequate vitamin D levels support a local, tissue-level defense mechanism where cells in the colon and prostate can produce the active hormone on site, independent of the kidneys.17The Journal of Nutrition. Phytoestrogens and Vitamin D Metabolism: A New Concept for the Prevention and Therapy of Colorectal, Prostate, and Mammary Carcinomas
Lycopene, the pigment that gives tomatoes their red color, is the other standout. Its antioxidant activity scavenges free radicals, prevents lipid oxidation, and activates the body’s own antioxidant defense enzymes.18PubMed. Antioxidant and anti-proliferative properties of lycopene Clinical and randomized controlled trials have examined lycopene supplementation across a range of cancers, with prostate cancer receiving the most attention. In prostate cancer specifically, lycopene supplementation has been associated with reduced PSA levels, a marker of disease activity.19PubMed Central. A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy The evidence for colorectal cancer is less definitive in humans, though animal studies have shown that lycopene supplementation inhibited colon tumor growth.20PubMed Central. The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies
Aspirin and Anti-Inflammatory Drugs
Daily aspirin use has attracted serious interest as a cancer prevention strategy, particularly for colorectal cancer. A review of observational studies found that regular use of anti-inflammatory drugs was associated with risk reductions of about 63% for colon cancer and about 39% for prostate cancer, though these are observational figures that likely overestimate the true effect.21PubMed. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade A more cautious meta-analysis focused on prostate cancer found that aspirin use was linked to a modest but real reduction in risk, with the association being slightly stronger for advanced disease. Long-term aspirin use of four or more years showed a statistically significant reduction in prostate cancer incidence.22PubMed Central. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis
The mechanism makes biological sense given the inflammation story. Aspirin blocks COX-2, an enzyme that drives the chronic inflammatory signaling that benefits tumors in both locations. But aspirin also increases the risk of gastrointestinal bleeding, so routine use for cancer prevention is not recommended for everyone. Current guidelines generally favor aspirin for people who already have cardiovascular indications and happen to get a colorectal cancer benefit as a bonus, rather than prescribing it purely for cancer prevention.
Statins and the Mixed Evidence
Statins have generated contradictory signals. Lab studies and observational data have suggested that statins reduce risk across several cancers, including both prostate and colorectal cancer, thanks to their anti-inflammatory and anti-proliferative properties.23PubMed Central. Statins in risk-reduction and treatment of cancer In the prostate specifically, statin users in one trial were less likely to have chronic prostate inflammation, which is thought to be a precursor to malignant changes.24PubMed Central. Statin use, serum lipids and prostate inflammation in men with a negative prostate biopsy: results from the REDUCE trial
However, a large meta-analysis that pooled data across thousands of cancer cases found that statins did not reduce cancer incidence or cancer deaths overall, and no reduction was seen for any individual cancer type.25JAMA. Statins and Cancer Risk: A Meta-analysis The disconnect likely comes down to the difference between what happens in a petri dish and what happens in a human body over decades. If you are already taking statins for heart disease, the possible anti-inflammatory benefits in cancer are a plausible bonus. But the evidence does not support starting statins for cancer prevention alone.
Environmental Exposures and Hormonal Disruption
Bisphenol A (BPA), found in certain plastics and food-container linings, has been linked to increased risk of hormone-sensitive cancers, including both prostate and colon cancer.26Current Molecular Pharmacology. The Endocrine Disruptor Bisphenol A (BPA) Exerts a Wide Range of Effects in Carcinogenesis and Response to Therapy BPA mimics estrogen and can interfere with the normal tumor-suppressing role of estrogen receptor beta. Since both the prostate and the colon rely on ERβ signaling to keep cell growth in check, chronic exposure to endocrine disruptors may quietly undermine a defense mechanism shared by both tissues.
This is an area where population-level data is still catching up to laboratory findings. Most people are exposed to BPA at low levels through food packaging, and regulatory agencies have taken steps to reduce exposure, especially in infant products. Whether typical adult exposure levels meaningfully increase cancer risk remains debated, but the biological plausibility is strong enough that minimizing unnecessary exposure is a reasonable precaution.
Where the Risks Diverge
Not every risk factor affects both cancers equally, and recognizing the differences is as useful as understanding the overlap. Ultra-processed food consumption, as noted earlier, showed a clear connection to colorectal cancer but not to prostate cancer in the studies available.6PubMed. Consumption of ultra-processed foods and drinks and colorectal, breast, and prostate cancer This makes some intuitive sense: the colon is in direct contact with the food you eat, while the prostate receives dietary influences only through the bloodstream.
Genetic risk also diverges in some areas. One study examining circadian rhythm gene variants found a significant association with prostate cancer risk but only a weak, unconfirmed signal for colorectal cancer. The most significant genes in the prostate association were NPAS2 and AANAT, both involved in the body’s internal clock and melatonin production. Disrupted circadian rhythms from shift work are a recognized risk factor for prostate cancer, but the link to colorectal cancer is much less established.
Screening strategies also differ considerably. Colorectal cancer screening through colonoscopy and stool-based tests is well established and broadly recommended starting around age 45. Prostate cancer screening with PSA testing has been more contentious due to concerns about overdiagnosis and overtreatment. Recent proposals, including those from a Lancet Commission, have pushed for risk-stratified screening that uses PSA as an initial filter, with MRI reserved for men whose results suggest elevated risk.27The Lancet Regional Health – Americas. Modernising prostate cancer screening in Canada: the case for organised and adaptive screening programs The goal is to catch dangerous cancers early while avoiding unnecessary biopsies and treatment for slow-growing tumors that would never cause harm.
Practical Prevention That Covers Both
The overlap between these two cancers means that a relatively short list of lifestyle habits works double duty. Eating less processed and red meat, maintaining a healthy weight, staying physically active, eating plenty of fiber-rich foods, and keeping vitamin D levels adequate address the shared metabolic, inflammatory, and microbiome pathways that feed both diseases. Adding tomato-based foods for lycopene is a low-cost addition with reasonable supporting evidence, especially for the prostate.
Where the cancers diverge, the strategies are additive rather than contradictory. Getting screened for colorectal cancer on schedule and discussing PSA testing with your doctor if you are in a higher-risk group covers the detection side. Reducing exposure to endocrine disruptors like BPA, while harder to quantify in terms of benefit, aligns with broader efforts to reduce unnecessary chemical exposures. The overall message is not that these are one disease with one fix. They are two distinct cancers that happen to share enough biology that taking care of one set of risk factors pulls the odds down for both.